Detailed information for compound 1973165

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 566.67 | Formula: C23H26N4O7S3
  • H donors: 3 H acceptors: 8 LogP: 0.44 Rotable bonds: 10
    Rule of 5 violations (Lipinski): 2
  • SMILES: O[C@H]1CCN(C1)C(=O)c1ccc(cc1)c1ccc2c(c1)sc(n2)C(S(=O)(=O)C)C(=O)NCCS(=O)(=O)N
  • InChi: 1S/C23H26N4O7S3/c1-36(31,32)20(21(29)25-9-11-37(24,33)34)22-26-18-7-6-16(12-19(18)35-22)14-2-4-15(5-3-14)23(30)27-10-8-17(28)13-27/h2-7,12,17,20,28H,8-11,13H2,1H3,(H,25,29)(H2,24,33,34)/t17-,20?/m0/s1
  • InChiKey: LXWUJPDUKVBQIR-DIMJTDRSSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens lipase, hepatic Starlite/ChEMBL No references
Homo sapiens lipase, endothelial Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Onchocerca volvulus 0.0048 0.183 0.4455
Brugia malayi hypothetical protein 0.0048 0.183 0.4811
Echinococcus granulosus conserved hypothetical protein 0.0013 0.0244 0.0196
Echinococcus multilocularis Polycystic kidney disease protein 0.0048 0.183 0.1892
Mycobacterium ulcerans transmembrane ABC transporter ATP-binding protein 0.0009 0.0062 0.5
Trypanosoma brucei ABC transporter, putative 0.0009 0.0062 0.5
Echinococcus multilocularis lipoxygenase domain containing protein 0.0048 0.183 0.1892
Echinococcus multilocularis conserved hypothetical protein 0.0013 0.0244 0.0196
Echinococcus granulosus Polycystic kidney disease protein 0.0048 0.183 0.1892
Plasmodium vivax hypothetical protein, conserved 0.0013 0.0244 0.1034
Plasmodium falciparum LCCL domain-containing protein 0.0048 0.183 1
Brugia malayi Uncharacterized hematopoietic stem/progenitor cells protein MDS029 0.0091 0.3804 1
Echinococcus granulosus RUN 0.0048 0.183 0.1892
Plasmodium falciparum CDGSH iron-sulfur domain-containing protein, putative 0.0013 0.0244 0.1034
Onchocerca volvulus 0.0048 0.183 0.4455
Echinococcus multilocularis cdgsh iron sulfur domain containing protein 0.0214 0.9412 1
Schistosoma mansoni rab6-interacting 0.0048 0.183 0.183
Brugia malayi hypothetical protein 0.0048 0.183 0.4811
Loa Loa (eye worm) hypothetical protein 0.0048 0.183 0.4811
Schistosoma mansoni rab6-interacting 0.0048 0.183 0.183
Schistosoma mansoni loxhd1 0.0048 0.183 0.183
Echinococcus granulosus cdgsh iron sulfur domain containing protein 0.0214 0.9412 1
Trypanosoma brucei ATP-binding cassette protein, putative 0.0009 0.0062 0.5
Onchocerca volvulus 0.0091 0.3804 1
Plasmodium falciparum CDGSH iron-sulfur domain-containing protein, putative 0.0013 0.0244 0.1034
Loa Loa (eye worm) hypothetical protein 0.0013 0.0244 0.0643
Schistosoma mansoni hypothetical protein 0.0013 0.0244 0.0244
Echinococcus granulosus lipoxygenase domain containing protein 0.0048 0.183 0.1892
Entamoeba histolytica ABC transporter, putative 0.0009 0.0062 0.5
Toxoplasma gondii zinc finger cdgsh type protein 0.0013 0.0244 1
Schistosoma mansoni hypothetical protein 0.0048 0.183 0.183
Brugia malayi RE40412p 0.0013 0.0244 0.0643
Brugia malayi RE40412p 0.0013 0.0244 0.0643
Leishmania major hypothetical protein, unknown function 0.0013 0.0244 1
Brugia malayi Doublecortin family protein 0.0048 0.183 0.4811
Schistosoma mansoni polycystin 1-related 0.0048 0.183 0.183
Plasmodium vivax hypothetical protein, conserved 0.0013 0.0244 0.1034
Echinococcus multilocularis RUN 0.0048 0.183 0.1892
Plasmodium vivax multidomain scavenger receptor, putative 0.0048 0.183 1
Toxoplasma gondii PfMNL-2 CISD1 family iron-sulfur protein, putative 0.0013 0.0244 1
Mycobacterium ulcerans transmembrane ABC transporter ATP-binding protein 0.0009 0.0062 0.5
Toxoplasma gondii zinc finger CDGSH-type domain-containing protein 0.0013 0.0244 1
Plasmodium falciparum CDGSH iron-sulfur domain-containing protein, putative 0.0013 0.0244 0.1034
Schistosoma mansoni hypothetical protein 0.0227 1 1
Loa Loa (eye worm) hypothetical protein 0.0091 0.3804 1
Mycobacterium ulcerans transmembrane ABC transporter ATP-binding protein 0.0009 0.0062 0.5
Trypanosoma cruzi ABC transporter, putative 0.0009 0.0062 0.5
Loa Loa (eye worm) doublecortin family protein 0.0048 0.183 0.4811
Plasmodium vivax hypothetical protein, conserved 0.0013 0.0244 0.1034
Echinococcus multilocularis lipoxygenase domain containing protein 0.0048 0.183 0.1892
Trypanosoma cruzi ATP-binding cassette protein, putative 0.0009 0.0062 0.5
Echinococcus granulosus lipoxygenase domain containing protein 0.0048 0.183 0.1892
Loa Loa (eye worm) hypothetical protein 0.0048 0.183 0.4811
Loa Loa (eye worm) hypothetical protein 0.0013 0.0244 0.0643
Schistosoma mansoni ATP-binding cassette sub-family g2 (white protein) (abcg2) 0.0009 0.0062 0.0062
Schistosoma mansoni lipoxygenase 0.0048 0.183 0.183
Giardia lamblia ABC transporter 0.0009 0.0057 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 1.8 nM Biological Assay BINDINGDB. No reference
IC50 (binding) = 4 nM Biological Assay BINDINGDB. No reference
IC50 (binding) = 261.6 nM BindingDB_Patents: Biological Assay. Endothelial lipase (EL) and hepatic lipase (HL) activities were measured using a fluorescent substrate, A10070, (Invitrogen, CA) doped into an artificial vesicle containing DMPG (Avanti Polar Lipids) as the excipient. Vesicles were prepared by combining 571 uL of 29 mM DMPG in a 1:1 mixture of MeOH and CHCl3 with 2000 uL of 1 mM A10070 in a 1:1 mixture of MeOH and CHCl3. The mixture was dried under nitrogen in multiple vials then resuspended in 20 mL total volume of 50 mM HEPES pH 8.0 buffer containing 50 mM NaCl and 0.2 mM EDTA. The sample was allowed to sit at room temperature for 15 min and then was sonicated 3x4 mins on ice with a Branson Sonicator using duty cycle 1. This preparation provides vesicles with a mole fraction of 0.11 for the FRET substrate.The enzymatic assay was measured using 384-well white Optiplates. Each well contained 20 uL of assay buffer (50 mM HEPES pH 8.0, 50 mM NaCl and 1 mM CaCl2) and 0.25 uL of a DMSO solution containing a compound. ChEMBL. No reference
IC50 (binding) = 2624 nM BindingDB_Patents: Biological Assay. Endothelial lipase (EL) and hepatic lipase (HL) activities were measured using a fluorescent substrate, A10070, (Invitrogen, CA) doped into an artificial vesicle containing DMPG (Avanti Polar Lipids) as the excipient. Vesicles were prepared by combining 571 uL of 29 mM DMPG in a 1:1 mixture of MeOH and CHCl3 with 2000 uL of 1 mM A10070 in a 1:1 mixture of MeOH and CHCl3. The mixture was dried under nitrogen in multiple vials then resuspended in 20 mL total volume of 50 mM HEPES pH 8.0 buffer containing 50 mM NaCl and 0.2 mM EDTA. The sample was allowed to sit at room temperature for 15 min and then was sonicated 3x4 mins on ice with a Branson Sonicator using duty cycle 1. This preparation provides vesicles with a mole fraction of 0.11 for the FRET substrate.The enzymatic assay was measured using 384-well white Optiplates. Each well contained 20 uL of assay buffer (50 mM HEPES pH 8.0, 50 mM NaCl and 1 mM CaCl2) and 0.25 uL of a DMSO solution containing a compound. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.